FMR1 and fragile X syndrome: Those studies should incorporate further refined methodologies [76] to assess whether parameters that may underlay variability in FXS, such as FMRP levels and comorbid diagnosis of ASD [7], have an impact on the response to those potential targeted therapeutics.